212 related articles for article (PubMed ID: 32346820)
1. Medical costs associated with metastatic breast cancer in younger, midlife, and older women.
Trogdon JG; Baggett CD; Gogate A; Reeder-Hayes KE; Rotter J; Zhou X; Ekwueme DU; Fairley TL; Wheeler SB
Breast Cancer Res Treat; 2020 Jun; 181(3):653-665. PubMed ID: 32346820
[TBL] [Abstract][Full Text] [Related]
2. An evaluation of the healthcare costs of metastatic breast cancer: A retrospective matched cohort study.
Chen HM; Chen JH; Chiang SC; Lin YC; Ko Y
Medicine (Baltimore); 2021 Oct; 100(43):e27567. PubMed ID: 34713830
[TBL] [Abstract][Full Text] [Related]
3. Breast cancer treatment costs in younger, privately insured women.
Allaire BT; Ekwueme DU; Poehler D; Thomas CC; Guy GP; Subramanian S; Trogdon JG
Breast Cancer Res Treat; 2017 Jul; 164(2):429-436. PubMed ID: 28432514
[TBL] [Abstract][Full Text] [Related]
4. Projecting the Prevalence and Costs of Metastatic Breast Cancer From 2015 through 2030.
Gogate A; Wheeler SB; Reeder-Hayes KE; Ekwueme DU; Fairley TL; Drier S; Trogdon JG
JNCI Cancer Spectr; 2021 Aug; 5(4):. PubMed ID: 34409255
[TBL] [Abstract][Full Text] [Related]
5. HER2-Positive Metastatic Breast Cancer: A Retrospective Cohort Study of Healthcare Costs in the Targeted-Therapy Age.
Sussell JA; Sheinson D; Wu N; Shah-Manek B; Seetasith A
Adv Ther; 2020 Apr; 37(4):1632-1645. PubMed ID: 32172510
[TBL] [Abstract][Full Text] [Related]
6. Medical costs of treating breast cancer among younger Medicaid beneficiaries by stage at diagnosis.
Trogdon JG; Ekwueme DU; Poehler D; Thomas CC; Reeder-Hayes K; Allaire BT
Breast Cancer Res Treat; 2017 Nov; 166(1):207-215. PubMed ID: 28702893
[TBL] [Abstract][Full Text] [Related]
7. Incidence-based cost-of-illness model for metastatic breast cancer in the United States.
Sorensen SV; Goh JW; Pan F; Chen C; Yardley D; Martín M; Knopf K; Benedict A; Giorgetti C; Iyer S
Int J Technol Assess Health Care; 2012 Jan; 28(1):12-21. PubMed ID: 22617734
[TBL] [Abstract][Full Text] [Related]
8. Indirect costs associated with metastatic breast cancer.
Wan Y; Gao X; Mehta S; Wang Z; Faria C; Schwartzberg L
J Med Econ; 2013 Oct; 16(10):1169-78. PubMed ID: 23866016
[TBL] [Abstract][Full Text] [Related]
9. Medical Care Costs of Breast Cancer in Privately Insured Women Aged 18-44 Years.
Allaire BT; Ekwueme DU; Guy GP; Li C; Tangka FK; Trivers KF; Sabatino SA; Rodriguez JL; Trogdon JG
Am J Prev Med; 2016 Feb; 50(2):270-7. PubMed ID: 26775906
[TBL] [Abstract][Full Text] [Related]
10. Comparison of medical costs and healthcare resource utilization of post-menopausal women with HR+/HER2- metastatic breast cancer receiving everolimus-based therapy or chemotherapy: a retrospective claims database analysis.
Li N; Hao Y; Koo V; Fang A; Peeples M; Kageleiry A; Wu EQ; Guérin A
J Med Econ; 2016; 19(4):414-23. PubMed ID: 27032967
[TBL] [Abstract][Full Text] [Related]
11. Treatment Costs of Breast Cancer Among Younger Women Aged 19-44 Years Enrolled in Medicaid.
Ekwueme DU; Allaire BT; Guy GP; Arnold S; Trogdon JG
Am J Prev Med; 2016 Feb; 50(2):278-85. PubMed ID: 26775907
[TBL] [Abstract][Full Text] [Related]
12. Real-World Analysis of Medical Costs and Healthcare Resource Utilization in Elderly Women with HR+/HER2- Metastatic Breast Cancer Receiving Everolimus-Based Therapy or Chemotherapy.
Hao Y; Li N; Fang AP; Koo V; Peeples M; Kageleiry A; Wu EQ; Guérin A
Adv Ther; 2016 Jun; 33(6):983-97. PubMed ID: 27216253
[TBL] [Abstract][Full Text] [Related]
13. Cost of illness associated with metastatic breast cancer.
Rao S; Kubisiak J; Gilden D
Breast Cancer Res Treat; 2004 Jan; 83(1):25-32. PubMed ID: 14997052
[TBL] [Abstract][Full Text] [Related]
14. Analysis of costs associated with administration of intravenous single-drug therapies in metastatic breast cancer in a U.S. population.
Kruse GB; Amonkar MM; Smith G; Skonieczny DC; Stavrakas S
J Manag Care Pharm; 2008; 14(9):844-57. PubMed ID: 19006441
[TBL] [Abstract][Full Text] [Related]
15. Productivity costs associated with metastatic breast cancer in younger, midlife, and older women.
Trogdon JG; Liu X; Reeder-Hayes KE; Rotter J; Ekwueme DU; Wheeler SB
Cancer; 2020 Sep; 126(18):4118-4125. PubMed ID: 32648979
[TBL] [Abstract][Full Text] [Related]
16. Concordance with NCCN treatment guidelines: Relations with health care utilization, cost, and mortality in breast cancer patients with secondary metastasis.
Rocque GB; Williams CP; Kenzik KM; Jackson BE; Azuero A; Halilova KI; Ingram SA; Pisu M; Forero A; Bhatia S
Cancer; 2018 Nov; 124(21):4231-4240. PubMed ID: 30317547
[TBL] [Abstract][Full Text] [Related]
17. Cost drivers for breast, lung, and colorectal cancer care in a commercially insured population over a 6-month episode: an economic analysis from a health plan perspective.
Sagar B; Lin YS; Castel LD
J Med Econ; 2017 Oct; 20(10):1018-1023. PubMed ID: 28581874
[TBL] [Abstract][Full Text] [Related]
18. Healthcare costs in postmenopausal women with hormone-positive metastatic breast cancer.
Lage MJ; Borker R; Barber B; Gao S
J Med Econ; 2010; 13(4):691-7. PubMed ID: 21070099
[TBL] [Abstract][Full Text] [Related]
19. The economic burden of metastatic breast cancer: a U.S. managed care perspective.
Montero AJ; Eapen S; Gorin B; Adler P
Breast Cancer Res Treat; 2012 Jul; 134(2):815-22. PubMed ID: 22684273
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant Chemotherapy Use and Health Care Costs After Introduction of Genomic Testing in Breast Cancer.
Epstein AJ; Wong YN; Mitra N; Vachani A; Hin S; Yang L; Smith-McLallen A; Armstrong K; Groeneveld PW
J Clin Oncol; 2015 Dec; 33(36):4259-67. PubMed ID: 26598749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
